IL6 and cancer: While evidence in pre-clinical cancer cachexia models have determined that different systemic inflammatory inhibitors, including IL-6, can attenuate several characteristics of cachexia [20, 27, 30], there is a limited understanding of the effect of these inhibitors after cachexia has developed, and whether short-term administration is sufficient to reverse cachexia-induced signaling in distinct target tissues.